La. Admin. Code tit. 48 § I-5712

Current through Register Vol. 50, No. 11, November 20, 2024

Section I-5712 - Onsite Access to Medication-Assisted Treatment

A. Each residential substance use disorder facility licensed as a BHS provider that provides treatment for opioid use disorder shall provide all of the following:

1. onsite access, as defined in the Rule, to at least one form of FDA-approved opioid antagonist treatment; and

2. onsite access, as defined in this Rule, to at least one form of FDA-approved partial opioid agonist treatment.

B. A residential substance use disorder facility licensed as a BHS provider shall not be found to be in violation of this Section if prior authorization from a patient's health insurer, a Medicaid program, is required, and the preapproval request is denied by the patient's health insurer.

C. Each residential substance use disorder facility licensed as a BHS provider which provides treatment for opioid use disorder shall submit to the department on its initial licensing application and/or its annual licensing renewal application an attestation as to whether it is complying with the requirements of §5712.A and when such compliance began.

D. If the licensed facility is not fully complying with the requirements of §5712 A, then the attestation that the facility submits to the department shall include a report addressing its progress toward satisfying the requirements of this Section.

La. Admin. Code tit. 48, § I-5712

Promulgated by the Department of Health, Bureau of Health Services Financing, LR 481287 (5/1/2022).

AUTHORITY NOTE: Promulgated in accordance with R.S. 36:254 and R.S. 40:2151-2161.